Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Conatus Pharmaceuticals CNAT

Healthcare Biotechnology
Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The company is developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activities of human caspases, which are enzymes... see more

Recent & Breaking News (NDAQ:CNAT)

22 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  April 3, 2017

Galectin Shares Upgraded To Buy; NASH-CX Results In December A 'Major Stock Catalyst'

Benzinga.com  March 30, 2017

Conatus to Present at Upcoming Investor Conferences

GlobeNewswire March 27, 2017

Conatus Pharmaceuticals Reports 2016 Financial Results and Program Updates

GlobeNewswire March 15, 2017

Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial Results

GlobeNewswire March 8, 2017

Research Reports Coverage on Biotech Stocks -- Anthera Pharma, Arrowhead Pharma, Pacific Biosciences of California, and Conatus Pharma

PR Newswire February 27, 2017

Conatus Pharmaceuticals Appoints William R. LaRue as Independent Board Member

GlobeNewswire February 7, 2017

Conatus to Present at BIO CEO & Investor Conference

GlobeNewswire February 6, 2017

Conatus Pharmaceuticals Promotes Daniel L. Ripley to Senior Vice President, Business Development, Program and Alliance Management

GlobeNewswire February 2, 2017

12 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  December 27, 2016

15 Biggest Mid-Day Gainers For Friday

Benzinga.com  December 23, 2016

Biotech Stocks Head Into 2017 With Clinical Developments That Could Lead to Growth and Added Value

PR Newswire December 21, 2016

Mid-Afternoon Market Update: Worthington Drops On Earnings Miss; Fred's Shares Spike Higher

Benzinga.com  December 20, 2016

Mid-Morning Market Update: Markets Open Higher; BlackBerry Earnings Beat Views

Benzinga.com  December 20, 2016

Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting

GlobeNewswire November 14, 2016

Conatus Pharmaceuticals to Present at Stifel 2016 Healthcare Conference

GlobeNewswire November 9, 2016

Conatus Pharmaceuticals Reports Third Quarter 2016 Financial Results and Program Updates

GlobeNewswire November 8, 2016

How These Biotech Stocks are Faring? -- Ocular Therapeutix, Idera Pharma, Conatus Pharma, and Infinity Pharma

PR Newswire November 4, 2016

Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis

GlobeNewswire November 3, 2016

Conatus Pharmaceuticals to Report Third Quarter 2016 Financial Results

GlobeNewswire November 1, 2016